The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Birtamimab (NEOD001): changing the treatment of amyloidosis
Traditional treatment of amyloidosis has been directed at the plasma cells responsible for the production of amyloid; however, that does not affect the deposit of amyloid already established. In this video, Morie Gertz, MD, MACP from the Mayo Clinic, Rochester, MN talks about the novel monoclonal antibody birtamimab (NEOD001), which binds directly to the amyloid fibers and can assist in the dissolution of those fibers. Data of a study using NEOD001 was presented at the European Hematology Association (EHA) 2017 meeting.
